U. Platzbecker - Leipzig University Hospital, Leipzig, Germany.

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 9 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

P1361: treatment of severe steroid-refractory acute gvhd with mesenchymal stromal cells: results of the phase iii randomized double-blind multi-center hovon-113 trial

L. Oosten,M. van Pel,B. van der Holt, E. Bach, M. Cross, H. Roelofs, P. Meij, B. Wieles,J. J. Zwaginga, A. Lankester, H. Veelken,U. Platzbecker,

HemaSphere（2022）

引用0浏览0引用

Changes In Transfusion Burden (Tb), Hemoglobin (Hb), Serum Ferritin (Sf), And Iron Chelation Therapy (Ict) Use In Patients With Lower-Risk Myelodysplastic Syndromes With Ring Sideroblasts Treated With Luspatercept From The Medalist Study

U. Platzbecker,G. Garcia-Manero,R. S. Komrokji,D. Tang,R. Ito, S. Fabre,G. Zhang,X. Ha, E. Mantovani, D. Miteva, T. Zinger,P. Fenaux

VALUE IN HEALTH（2021）

引用0浏览0引用

Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III

A.M. Zeidan, J. Garcia,P. Fenaux,U. Platzbecker, Y. Miyazaki, Z. Xiao, Y. Zhou, K. Naqvi,S. Kye,G. Garcia Manero

Leukemia Research (2021): 106681.51-106681.51

引用0浏览0引用

Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III: PHASE 3 VERONA STUDY ASSESSING THE SAFETY AND EFFICACY OF VENETOCLAX WITH AZACITIDINE IN PATIENTS WITH NEWLY DIAGNOSED HIGHER-RISK MYELODYSPLASTIC SYNDROMES

A.M. Zeidan,J. Garcia, P. Fenaux,U. Platzbecker, Y. Miyazaki, Z. Xiao, Y. Zhou, K. Naqvi,S. Kye,G. Garcia Manero

Leukemia Research（2021）

引用0浏览0引用

Isolated der (1;7) fits well in the intermediate risk group of the cytogenetic scoring system for myelodysplastic syndromes

C. Ganster,C. Mueller-Thomas, C. Haferlach, C. Strupp, K. Ogata, U. Germing,B. Hildebrandt,M. Mallo,M. Luebbert,C. Mueller, F. Sole, K. Goetze,

ONCOLOGY RESEARCH AND TREATMENT（2019）

引用0浏览0引用

First results of the EUROPE-Trial: validation of a new predictive model of response to romiplostim in patients with IPSS low risk myelodysplastic syndrome (MDS) and thrombocytopenia

A. S. Kubasch,A. Giagounidis,G. Metzgeroth,K. Sockel, A. Jonasova,R. Herbst, Torregrosa J. M. Diaz,B. De Renzis, K. Goetze, M. -L. Huetter-Kroenke, M. -P. Gourin, B. Slama,

ONCOLOGY RESEARCH AND TREATMENT（2019）

引用0浏览0引用

Comprehensive RNA-sequencing analysis indicates a heterogeneous pathogenesis of early death events in acute promyelocytic leukemia

A. Streuer,J. -C. Jann, de Gutierrez A. Hecht, F. Nolte,U. Platzbecker, V Nowak,J. Danner, J. Oblaender, I Palme, N. Draeger, E. Lengfelder, W. -K Hofmann,

ONCOLOGY RESEARCH AND TREATMENT（2019）

引用0浏览0引用

S837 treatment with imetelstat provides durable transfusion independence (ti) in heavily transfused non-del(5q) lower risk mds (lr-mds) relapsed/refractory (r/r) to erythropoiesis stimulating agents (esas)

P. Fenaux,D.P. Steensma, K. Van Eygen, A. Raza, V. Santini, U. Germing, P. Font, M. Díez-Campelo, S. Thepot, E. Vellenga, M.M. Patnaik, J.H. Jang,

HemaSphereno. S1 (2019): 372-373

引用6浏览0引用

Clonal evolution is much more common in myelodysplastic syndromes than previously described and closely related to clinical progression

C. Ganster, K. Shirneshan, S. Dierks,R. Martin,B. Glass,H. K. Al-Ali,M. Metz, U. Germing,U. Platzbecker,C. Mueller-Thomas, K. S. Goetze, N. Kroeger,

ONCOLOGY RESEARCH AND TREATMENT（2018）

引用0浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn